抗血栓药物围手术期管理多学科专家共识

2020-10-27 中国心胸血管麻醉学会 中华医学杂志.2020.100(39):3058-3074.

随着我国老龄人口的增多,以及对血栓性疾病管理规范化水平的不断提高,术前长期服用抗血栓药物患者在外科手术患者中所占比例也在不断增加。抗血栓药物主要包括抗凝药物、抗血小板药物和纤溶药物。术前长期服用抗血栓

中文标题:

抗血栓药物围手术期管理多学科专家共识

发布日期:

2020-10-27

简要介绍:

随着我国老龄人口的增多,以及对血栓性疾病管理规范化水平的不断提高,术前长期服用抗血栓药物患者在外科手术患者中所占比例也在不断增加。抗血栓药物主要包括抗凝药物、抗血小板药物和纤溶药物。术前长期服用抗血栓药物(抗凝药物和抗血小板药物)的患者,围手术期如继续服用可增加手术出血风险,而停用则可致血栓栓塞事件的风险增加。鉴于出血和血栓栓塞对患者近远期预后均有重要不良影响,如何平衡两种风险至关重要,有时需多学科协作评估以制定个体化的患者管理方案。本共识结合目前国内外最新的证据和指南,并通过相关多学科专家的讨论,针对内科常见血栓栓塞疾病的血栓栓塞风险分级、外科手术出血风险分级、抗血栓药物的停药时机和桥接方案、择期与急诊外科手术围手术期抗血栓药物的管理以及区域阻滞麻醉与抗血栓药物管理等形成推荐意见,以期降低此类患者围手术期主要心脑血管事件和出血不良事件的发生率,保障患者围手术期安全。

 

下载附件:

(因为版权问题,不支持下载)

评论区 (36)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1206216, encodeId=b4da120621627, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220625/6f4f075937de4c5d9fc7ab3a1bc6d8c2/13a8a29e67044698af1fb74276589093.jpg, createdBy=b5c55099112, createdName=D-House, createdTime=Sat Mar 26 20:35:03 CST 2022, time=2022-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1080973, encodeId=7fd410809e375, content=非常好shiy, beContent=null, objectType=guider, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d25a5516768, createdName=一己怀, createdTime=Fri Dec 17 01:02:43 CST 2021, time=2021-12-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1080972, encodeId=adce10809e2ce, content=非常好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d25a5516768, createdName=一己怀, createdTime=Fri Dec 17 01:02:36 CST 2021, time=2021-12-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1076961, encodeId=5b6410e696168, content=非常好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211204/69ac3a99bfa54b1f9891fe32e1e0208a/d4430e8c069f415280a188758e6a9ed9.jpg, createdBy=f9f45211246, createdName=诡秘小刀, createdTime=Sun Dec 05 00:01:46 CST 2021, time=2021-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=976546, encodeId=10e39e6546e0, content=很有帮助, beContent=null, objectType=guider, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210524/a0c352956dd542e6a9c70a15047728f3/5341adc093b846d7b348d5349bbda945.jpg, createdBy=64ea5294279, createdName=青囊, createdTime=Thu Jun 24 16:10:31 CST 2021, time=2021-06-24, status=1, ipAttribution=)]
    2022-03-26 D-House

    学习

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1206216, encodeId=b4da120621627, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220625/6f4f075937de4c5d9fc7ab3a1bc6d8c2/13a8a29e67044698af1fb74276589093.jpg, createdBy=b5c55099112, createdName=D-House, createdTime=Sat Mar 26 20:35:03 CST 2022, time=2022-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1080973, encodeId=7fd410809e375, content=非常好shiy, beContent=null, objectType=guider, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d25a5516768, createdName=一己怀, createdTime=Fri Dec 17 01:02:43 CST 2021, time=2021-12-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1080972, encodeId=adce10809e2ce, content=非常好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d25a5516768, createdName=一己怀, createdTime=Fri Dec 17 01:02:36 CST 2021, time=2021-12-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1076961, encodeId=5b6410e696168, content=非常好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211204/69ac3a99bfa54b1f9891fe32e1e0208a/d4430e8c069f415280a188758e6a9ed9.jpg, createdBy=f9f45211246, createdName=诡秘小刀, createdTime=Sun Dec 05 00:01:46 CST 2021, time=2021-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=976546, encodeId=10e39e6546e0, content=很有帮助, beContent=null, objectType=guider, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210524/a0c352956dd542e6a9c70a15047728f3/5341adc093b846d7b348d5349bbda945.jpg, createdBy=64ea5294279, createdName=青囊, createdTime=Thu Jun 24 16:10:31 CST 2021, time=2021-06-24, status=1, ipAttribution=)]
    2021-12-17 一己怀

    非常好shiy

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1206216, encodeId=b4da120621627, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220625/6f4f075937de4c5d9fc7ab3a1bc6d8c2/13a8a29e67044698af1fb74276589093.jpg, createdBy=b5c55099112, createdName=D-House, createdTime=Sat Mar 26 20:35:03 CST 2022, time=2022-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1080973, encodeId=7fd410809e375, content=非常好shiy, beContent=null, objectType=guider, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d25a5516768, createdName=一己怀, createdTime=Fri Dec 17 01:02:43 CST 2021, time=2021-12-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1080972, encodeId=adce10809e2ce, content=非常好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d25a5516768, createdName=一己怀, createdTime=Fri Dec 17 01:02:36 CST 2021, time=2021-12-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1076961, encodeId=5b6410e696168, content=非常好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211204/69ac3a99bfa54b1f9891fe32e1e0208a/d4430e8c069f415280a188758e6a9ed9.jpg, createdBy=f9f45211246, createdName=诡秘小刀, createdTime=Sun Dec 05 00:01:46 CST 2021, time=2021-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=976546, encodeId=10e39e6546e0, content=很有帮助, beContent=null, objectType=guider, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210524/a0c352956dd542e6a9c70a15047728f3/5341adc093b846d7b348d5349bbda945.jpg, createdBy=64ea5294279, createdName=青囊, createdTime=Thu Jun 24 16:10:31 CST 2021, time=2021-06-24, status=1, ipAttribution=)]
    2021-12-17 一己怀

    非常好

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1206216, encodeId=b4da120621627, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220625/6f4f075937de4c5d9fc7ab3a1bc6d8c2/13a8a29e67044698af1fb74276589093.jpg, createdBy=b5c55099112, createdName=D-House, createdTime=Sat Mar 26 20:35:03 CST 2022, time=2022-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1080973, encodeId=7fd410809e375, content=非常好shiy, beContent=null, objectType=guider, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d25a5516768, createdName=一己怀, createdTime=Fri Dec 17 01:02:43 CST 2021, time=2021-12-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1080972, encodeId=adce10809e2ce, content=非常好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d25a5516768, createdName=一己怀, createdTime=Fri Dec 17 01:02:36 CST 2021, time=2021-12-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1076961, encodeId=5b6410e696168, content=非常好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211204/69ac3a99bfa54b1f9891fe32e1e0208a/d4430e8c069f415280a188758e6a9ed9.jpg, createdBy=f9f45211246, createdName=诡秘小刀, createdTime=Sun Dec 05 00:01:46 CST 2021, time=2021-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=976546, encodeId=10e39e6546e0, content=很有帮助, beContent=null, objectType=guider, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210524/a0c352956dd542e6a9c70a15047728f3/5341adc093b846d7b348d5349bbda945.jpg, createdBy=64ea5294279, createdName=青囊, createdTime=Thu Jun 24 16:10:31 CST 2021, time=2021-06-24, status=1, ipAttribution=)]
    2021-12-05 诡秘小刀

    非常好

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1206216, encodeId=b4da120621627, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220625/6f4f075937de4c5d9fc7ab3a1bc6d8c2/13a8a29e67044698af1fb74276589093.jpg, createdBy=b5c55099112, createdName=D-House, createdTime=Sat Mar 26 20:35:03 CST 2022, time=2022-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1080973, encodeId=7fd410809e375, content=非常好shiy, beContent=null, objectType=guider, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d25a5516768, createdName=一己怀, createdTime=Fri Dec 17 01:02:43 CST 2021, time=2021-12-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1080972, encodeId=adce10809e2ce, content=非常好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d25a5516768, createdName=一己怀, createdTime=Fri Dec 17 01:02:36 CST 2021, time=2021-12-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1076961, encodeId=5b6410e696168, content=非常好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211204/69ac3a99bfa54b1f9891fe32e1e0208a/d4430e8c069f415280a188758e6a9ed9.jpg, createdBy=f9f45211246, createdName=诡秘小刀, createdTime=Sun Dec 05 00:01:46 CST 2021, time=2021-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=976546, encodeId=10e39e6546e0, content=很有帮助, beContent=null, objectType=guider, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210524/a0c352956dd542e6a9c70a15047728f3/5341adc093b846d7b348d5349bbda945.jpg, createdBy=64ea5294279, createdName=青囊, createdTime=Thu Jun 24 16:10:31 CST 2021, time=2021-06-24, status=1, ipAttribution=)]
    2021-06-24 青囊

    很有帮助

    0

拓展阅读

2015 ASGE指南:胃肠道内窥镜检查患者抗血栓形成药物的管理

美国胃肠内镜学会(ASGE,American Society for Gastrointestinal Endoscopy) · 2015-11-24

中国抗血栓药物相关出血诊疗规范专家共识 (2022年)

武汉亚洲心脏病医院检验科 · 2022-10-12

2022 ISTH指南:使用抗血栓药物或合并血小板减少的肿瘤患者进行侵入性操作时的围手术期管理

国际血栓与止血学会(ISTH,International Society on Thrombosis and Haemostasis) · 2022-12-20